Hashemian H.M.,AMS Services |
Bean W.C.,Lamar University
IEEE Transactions on Instrumentation and Measurement | Year: 2011
This paper discusses the limitations of time-based equipment maintenance methods and the advantages of predictive or online maintenance techniques in identifying the onset of equipment failure. The three major predictive maintenance techniques, defined in terms of their source of data, are described as follows: 1) the existing sensor-based technique; 2) the test-sensor-based technique (including wireless sensors); and 3) the test-signal-based technique (including the loop current step response method, the time-domain reflectrometry test, and the inductance-capacitance-resistance test). Examples of detecting blockages in pressure sensing lines using existing sensor-based techniques and of verifying calibration using existing-sensor direct current output are given. Three Department of Energy (DOE)-sponsored projects, whose aim is to develop online and wireless hardware and software systems for performing predictive maintenance on critical equipment in nuclear power plants, DOE research reactors, and general industrial applications, are described. © 2011 IEEE.
Serth K.,Institute For Molekularbiologie Oe5250 |
Schuster-Gossler K.,Institute For Molekularbiologie Oe5250 |
Kremmer E.,Helmholtz Center for Environmental Research |
Hansen B.,Institute For Molekularbiologie Oe5250 |
And 3 more authors.
PLoS ONE | Year: 2015
Delta-like 3 (DLL3) is a member of the DSL family of Notch ligands in amniotes. In contrast to DLL1 and DLL4, the other Delta-like proteins in the mouse, DLL3 does not bind in trans to Notch and does not activate the receptor, but shows cis-interaction and cis-inhibitory properties on Notch signaling in vitro. Loss of the DSL protein DLL3 in the mouse results in severe somite patterning defects, which are virtually indistinguishable from the defects in mice that lack lunatic fringe (LFNG), a glycosyltransferase involved in modifying Notch signaling. Like LFNG, DLL3 is located within the trans-Golgi, however, its biochemical function is still unclear. Here, we show that i) both proteins interact, ii) epidermal growth factor like repeats 2 and 5 of DLL3 are O-fucosylated at consensus sites for POFUT1, and iii) further modified by FNG proteins in vitro. Embryos double homozygous for null mutations in Dll3 and Lfng are phenotypically indistinguishable from the single mutants supporting a potential common function. Mutation of the O-fucosylation sites in DLL3 does not disrupt the interaction of DLL3 with LFNG or full length Notch1or DLL1, and O-fucosylation-deficient DLL3 can still inhibit Notch in cis in vitro. However, in contrast to wild type DLL3, O-fucosylation-deficient DLL3 cannot compensate for the loss of endogenous DLL3 during somitogenesis in the embryo. Together our results suggest that the cis-inhibitory activity of DLL3 observed in cultured cells might not fully reflect its assumed essential physiological property, suggest that DLL3 and LFNG act together, and strongly supports that modification of DLL3 by O-linked fucose is essential for its function during somitogenesis. © 2015 Serth et al.
Ringe J.D.,Klinikum Leverkusen GmbH |
Schafer S.,AMS Services |
Wimmer A.M.,Janssen Cilag GmbH |
Giesecke T.,Janssen Cilag GmbH
Wiener Klinische Wochenschrift | Year: 2012
Objective: To determine the effect of a lower starting dose of OROS ® hydromorphone compared with a higher starting dose. Design: Data from the first 15 days of treatment were compared in a combined analysis of three prospective, non-interventional studies. Setting: Non-interventional, carried out in daily routine settings. Patients: Patients had chronic severe pain due to osteoarthritis or from fragility fractures related to osteoporosis. Interventions: OROS-ANA-4001 and OROS-ANA-4002 had a daily starting dose of 8 mg of OROS ® hydromorphone; OROS-ANA-4003 had a daily starting dose of 4 mg. Main Outcome Measure(s): A post-hoc analysis to assess the effect of a low starting dose of OROS ® hydromorphone on tolerability, pain control, and treatment satisfaction overall and for subgroups of opioid-naïve patients versus patients previously treated with opioids, and patients aged>65 years versus patients aged≤65 years. Results: Treatment satisfaction and pain control improved in all studies; treatment satisfaction improved in a higher percentage ofipatients in the lower starting dose group. Gastrointestinal disorders were the most frequent treatment-emergent adverse events. Incidence ofinausea was comparable between studies. Incidence of constipation, vomiting, fatigue, and pruritus was less frequent with the lower starting dose. In elderly and opioid-naïve patients, a lower starting dose was associated with lower overall incidence of adverse events, treatment-related adverse events, and those leading to discontinuation. Conclusions: A lower starting dose was associated with better tolerability and a lower number of treatment terminations at a comparable level of pain control with high treatment satisfaction. © Springer-Verlag 2012.
Brooks M.S.,AMS Services
Bulletin of the American Meteorological Society | Year: 2013
Mark S. Brooks suggests that engagement, entrepreneurship, and evaluation are the key drivers of innovative and transformative services that will help citizens, businesses, and governments manage climate risks. Innovations are needed to help citizens, businesses, and governments deal with the impacts of climate change and variability. Climate services provide decision support with climate data, future projections, applied research, and integration with other environmental or socioeconomic datasets and models. Climate services at all levels help clients manage climate-related risks and capitalize on favorable conditions. These services focus on long-term decision support early warning systems and help clients understand the impact of climate on their decisions and actions. A climate services enterprise that enables discontinuous, disruptive, and transformative innovations will help climate sensitive clients solve problems in new ways with new data products and services.
Diepgen T.L.,University of Heidelberg |
Pfarr E.,AMS Services |
Zimmermann T.,Basilea Pharmaceutica Deutschland GmbH
Acta Dermato-Venereologica | Year: 2012
This non-interventional observational open study (TOCCATA, sponsored by Basilea Pharmaceutica Germany) investigated the use of alitretinoin to treat chronic hand eczema under daily "real life" medical practice conditions in Germany. A total of 349 dermatologists throughout Germany enrolled 680 adult patients with chronic hand eczema. Patients were prescribed and treated with alitretinoin in accordance with the summary of product characteristics. The maximum observation duration was 24 weeks, with efficacy and safety parameters evaluated every 4 weeks. Efficacy was primarily evaluated by assessing disease severity according to the Physician Global Assessment. In total, 56.7% of patients achieved a Physician Global Assessment rating of "clear" or "almost clear" hands, with only small differences in patients with different morphological forms: hyperkeratotic-rhagadiform (59.2%), fingertip (52.2%) and vesicular (47.9%). This observational study demonstrates the effectiveness and tolerability of alitretinoin in everyday clinical practice in addition to the known efficacy and safety obtained by randomized controlled clinical trials. © 2012 The Authors.